{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-088236","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.087047+00:00","generated_at":"2026-05-31T14:25:20.393641+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fulcrum Therapeutics reports Q2 net income of $55.4M, on track for Phase 3 FSHD data by Oct 2024","bullets":["Net income $55.4M vs net loss $23.8M in Q2 2023; revenue $80M from Sanofi upfront payment.","Cash and securities $273.8M as of June 30, 2024; expected to fund operations into 2027.","Phase 3 REACH trial (losmapimod for FSHD) topline data expected by end of October 2024; 260 patients enrolled.","Collaboration with Sanofi for ex-U.S. losmapimod; $80M upfront received in Q2.","Phase 1b pociredir (SCD) advancing; cohorts at 12 mg and 20 mg once daily planned."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-088236","json":"https://secwatch.observer/filing/0000950170-24-088236.json","markdown":"https://secwatch.observer/filing/0000950170-24-088236.md","text":"https://secwatch.observer/filing/0000950170-24-088236.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000095017024088236/0000950170-24-088236-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000095017024088236/fulc-20240731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:25:20.393641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}